1. Scrip
  2. >>Business

AZ BioVentureHub CEO Says Aim Is Innovative Scandinavian Ecosystem

 
• By Mike Ward

AstraZeneca’s BioVentureHub CEO Magnus Björsne tells Mike Ward about the exchange's intention to generate a climate of open innovation to help grow and nurture the Scandinavian life science ecosystem.

Magnus Bjorsne

AstraZeneca’s BioVentureHub is helping generate a climate of open innovation to help grow and nurture the Scandinavian life science ecosystem, according to the exchange's CEO. AZ BioVentureHub was established in 2014 in Gothenberg, Sweden, aimed at drawing together emerging biotech and medtech businesses and academic groups. It has already has attracted 18 companies, one academic group, four external sponsors and two scientific partners, the hub's head Magnus Björsne says in a television interview.

Open Media

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from Business

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 
• By Andrew McConaghie

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

Cipla Revs Up Biosimilars Engine Amid Winds Of Regulatory Change

 
• By Anju Ghangurde

Cipla’s partnered filgrastim biosimilar is expected to debut in the US in Q2 FY26 and the Indian firm expects an investment return ratio for its biosimilar engine “not too far” from that of a complex generic product amid an enabling regulatory environment.

With Planned US Facility Acquisition, Celltrion Looks To Avoid US Pharma Tariffs

 
• By Jung Won Shin

Celltrion is set to acquire a US biologics manufacturing facility that will "eliminate" its US tariff risks and provide a ready-made production base for future expansion.

Merck & Co.’s Winrevair Growing Into The Revenue Driver Needed Post-Keytruda LOE

 
• By Mandy Jackson

PAH drug Winrevair generated more than $1bn in sales in its first year on the US market, but the company plans to cut $3bn in costs through 2027 that it will reinvest in additional growth drivers.

More from Scrip

Merck & Co.’s Winrevair Growing Into The Revenue Driver Needed Post-Keytruda LOE

 
• By Mandy Jackson

PAH drug Winrevair generated more than $1bn in sales in its first year on the US market, but the company plans to cut $3bn in costs through 2027 that it will reinvest in additional growth drivers.

PTC To Challenge BioMarin In PKU With Oral Sephience

 
• By Joseph Haas

PTC plans to compete with BioMarin’s two phenylketonuria drugs with efficacy data showing strong reduction of phenylalanine and ability for patients to liberalize their diets.

Novo Selects Internal CEO To Recharge Growth

 
• By Jessica Merrill

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.